RecruitingPhase 4NCT07598214

Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients

Evaluation of the Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients: A Randomized Controlled Trial

Sponsor

Beni-Suef University

Enrollment

100 participants

Start Date

Feb 3, 2025

Study Type

INTERVENTIONAL

Conditions

Cancer Patients

Summary

The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria1

Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.

Exclusion Criteria7

History of allergic reactions attributed to drugs in the study.
Pregnant women.
Life expectancy less than 6 months
Inability or unwillingness to comply with research protocols.
Cancer patients with impaired renal function (creatinine clearance < 50 mL/min)
Preexisting hearing loss.
Patients taking nephrotoxic drugs; and those who have a history of allergic reactions to platinum-containing compounds.

Interested in this trial?

Get notified about updates and connect with the research team.